Back to Home
Home >> Biotechnology /Genomics and Intellectual Property >>Patenting of Biological Material >>International Conventions
Back to Home

International Conventions
In connection with intellectual properties dealing with biological material, there are international conventions, which do not allow patents for processes or products dealing with alleviation of human disease.
For instance, it is not possible to patent techniques for surgery such as by-pass heart surgery, organ transplants, implant of heart valves, artificial limbs, dialysis for renal failure, plastic surgery and other surgical methods used in cancer, appendicitis or neurosurgery.
Similarly, one can not patent the following: (i) the use of drugs, antibiotics or vaccines for any form of diagnosis, prevention or cure of diseases, (ii) artificial insemination, and (iii) in vitrofertilization and embryo transfer, etc.

In plant biotechnology also, live plants (not the transgenic plants), naturally occurring microorganisms, micropropagation, tissue and organ culture techniques, biological control of pests, and hybrid varieties can not be protected using patents.
Even techniques for cell fusion, protoplast fusion and gene transfer can not be generally protected through patents. Commercial benefits from hybrid varieties can, however, be secured through control of parent plants, which may be a trade secret. Similarly, although new crop varieties can not be patented, but transgenic animals and plants can be patented, although there may be arguments against it. Crop varieties, however, can be protected through plant breeders' rights i.e., PBRs.

In case of microorganisms selected for production of antibiotics, amino acids, enzymes, alcohol, etc., patent protection is generally not available, although under specific situations, protection for microorganisms modified for commercial use may be allowed.
In these cases (e.g. fermentation), generally commercial benefits are derived by contracts involving transfer of technology through restrictions on further transfer to third parties. Thus, trade secrecy rather than patents in such cases protect the commercial benefit.